Solbec progresses psoriasis trial
Tuesday, 05 October, 2004
Solbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
The drug, formulated as a cream, was tested on a number of healthy individuals with no unwanted effects or reactions recorded. The company will now move on to test the treatment at a therapeutic dose, in preparation for larger Phase II trials, expected to commence after the Phase I trial winds up in early 2005.
The clinical trials are being conducted by clinical trials unit CMAX, part of listed Australian company IDT, in Adelaide.
SBP002 is also under investigation by Solbec as a cancer treatment for mesothelioma and melanoma.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
